Astria Therapeutics (NASDAQ:ATXS) Shares Down 3.4% – What’s Next?

Astria Therapeutics, Inc. (NASDAQ:ATXS)’s share price dropped 3.4% during trading on Thursday . The company traded as low as $9.22 and last traded at $9.22. Approximately 20,860 shares changed hands during mid-day trading, a decline of 96% from the average daily volume of 587,191 shares. The stock had previously closed at $9.54.

Analyst Upgrades and Downgrades

A number of brokerages have recently issued reports on ATXS. Oppenheimer increased their target price on Astria Therapeutics from $26.00 to $28.00 and gave the company an “outperform” rating in a research report on Thursday, November 14th. HC Wainwright restated a “buy” rating and set a $16.00 price objective on shares of Astria Therapeutics in a research report on Tuesday, December 10th. Five research analysts have rated the stock with a buy rating and one has issued a strong buy rating to the stock. According to MarketBeat, the company presently has a consensus rating of “Buy” and a consensus target price of $25.60.

Astria Therapeutics Stock Down 2.9 %

The company has a 50-day moving average of $10.45 and a 200 day moving average of $10.71. The stock has a market capitalization of $516.37 million, a PE ratio of -4.38 and a beta of 0.67.

Institutional Investors Weigh In On Astria Therapeutics

A number of hedge funds have recently modified their holdings of ATXS. Quest Partners LLC boosted its position in Astria Therapeutics by 3,310.6% during the second quarter. Quest Partners LLC now owns 3,206 shares of the biotechnology company’s stock worth $29,000 after acquiring an additional 3,112 shares during the last quarter. PDT Partners LLC acquired a new position in shares of Astria Therapeutics during the 3rd quarter worth approximately $140,000. SG Americas Securities LLC purchased a new stake in shares of Astria Therapeutics in the third quarter valued at approximately $155,000. Hsbc Holdings PLC acquired a new stake in shares of Astria Therapeutics in the second quarter valued at approximately $171,000. Finally, Intech Investment Management LLC acquired a new stake in shares of Astria Therapeutics in the third quarter valued at approximately $228,000. 98.98% of the stock is currently owned by institutional investors and hedge funds.

About Astria Therapeutics

Astria Therapeutics, Inc, a biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutics for allergic and immunological diseases in the United States. Its lead product candidate is STAR-0215, a monoclonal antibody inhibitor of plasma kallikrein, which is in Phase 1b/2 clinical trials for the treatment of hereditary angioedema.